Caicedo A, Morales E, Moyano A, et al
A recent clinical trial in type 2 diabetes patients with CVDs following captopril treatment (12.5 mg/day, P.O for 3 months) found a significant improvement in plasma GSH levels and a concomitant decline in lipid peroxidation [241]
TRIUMPH-4 confirmed: Retatrutide 28.7% weight loss in Phase 3 (December 2025) final data, not preliminary TRIUMPH-1 confirmed (May 21, 2026): 28.3% average weight loss at 80 weeks in 2,339 patients without diabetes pivotal trial met all primary endpoints TRANSCEND-T2D-1 confirmed (June 2026): -2.0% HbA1c and 16.8% weight loss in type 2 diabetes patients a separate diabetes-specific Phase 3 program Filing timeline updated: Eli Lilly will submit a Biologics License Application (BLA) not an NDA, since retatrutide is a biologic expected Q1 2027 (shifted from the previously estimated Q4 2026) Availability updated: Retatrutide remains investigational
Cordani M, Butera G, Pacchiana R, Masetto F, Mullappilly N, Riganti C, et al